. 2016 Aug 2;8:397–406. doi: 10.2147/CEOR.S91844

Table 1.

Model estimates: clinical assumptions

Clinical parameter	Model estimate	Reference
Survival assumptions
Stage IIIC survival ovarian cancer
1-year survival treated with PDS	90.7%	National Cancer Institute²⁶
2-year survival treated with PDS	70.5%	National Cancer Institute²⁶
3-year survival treated with PDS	54.3%	National Cancer Institute²⁶
4-year survival treated with PDS	41.2%	National Cancer Institute²⁶
5-year survival treated with PDS	33.4%	National Cancer Institute²⁶
1-year survival treated with NACT	89.7%	National Cancer Institute²⁶
2-year survival treated with NACT	65.6%	National Cancer Institute²⁶
3-year survival treated with NACT	41.8%	National Cancer Institute²⁶
4-year survival treated with NACT	32.3%	National Cancer Institute²⁶
5-year survival treated with NACT	24.1%	National Cancer Institute²⁶
Stage IV survival ovarian cancer
1-year survival treated with PDS	87.2%	National Cancer Institute²⁶
2-year survival treated with PDS	62.1%	National Cancer Institute²⁶
3-year survival treated with PDS	45.2%	National Cancer Institute²⁶
4-year survival treated with PDS	33.2%	National Cancer Institute²⁶
5-year survival treated with PDS	24.7%	National Cancer Institute²⁶
1-year survival treated with NACT	88.8%	National Cancer Institute²⁶
2-year survival treated with NACT	60.2%	National Cancer Institute²⁶
3-year survival treated with NACT	40.6%	National Cancer Institute²⁶
4-year survival treated with NACT	25.4%	National Cancer Institute²⁶
5-year survival treated with NACT	17.7%	National Cancer Institute²⁶
Utility weights
Months 1–5 following chemotherapy	0.77	Chi et al⁵
Months 6–12 following chemotherapy	0.88	Chi et al⁵
Year 2 living with ovarian cancer	0.94	Chi et al⁵
Years 3–5 living with ovarian cancer	0.5	Chi et al⁵

Abbreviations: NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.